Results 111 to 120 of about 67,431 (260)

Elucidating the role of the tumor suppressor Protein Phoshatase 2A in Chronic Myeloid Leukemia.

, 2010
Protein phosphatase-2A (PP2A) is one of the major cellular serine-threonine phosphatases and is involved in the regulation of cell homeostasis through the negative regulation of signaling pathways initiated by protein kinases.
Neviani, Paolo
core  

Force profiles of imatinib dissociation from imatinib-Abl complex.

, 2013
(A) Force profile of imatinib unbinding along ATP-channel. (B) Force profile of imatinib unbinding along allosteric-pocket-channel. (C) Averaged force profiles of imatinib unbinding along ATP-channel (red) and allosteric-pocket-channel (black).
Jun Zou (683), Huan-Zhang Xie (368262), Sheng-Yong Yang (192164), Li-Jun Yang (368261), Lin-Li Li (192153), Yu-Quan Wei (192158)   +5 more
core   +1 more source

A novel JAK1 variant in chronic eosinophilic leukaemia with response to benralizumab

British Journal of Haematology, EarlyView.
Isabel C. Vallecillo‐Viejo, Michael D. Claiborne, Charles F. Anderson, Samantha Shafer, Alan Saven, Bryce A. Seifert, Morgan Similuk, Magdalena Walkiewicz, Irina Maric, Pia R. Crespo, Lori Broderick, Andrew A. White, Amy D. Klion   +12 more
wiley   +1 more source

Personalized Dose of Adjuvant Imatinib in Patients with Gastrointestinal Stromal Tumors: Results from a Population Pharmacokinetic Analysis

, 2023
Xuehui Jiang,1,2 Qun Fu,3 Yan Jing,4 Ying Kong,2 Hong Liu,2 Hongwei Peng,2 Kaisaner Rexiti,1,2 Xiaohua Wei2 1School of Pharmacy, Nanchang University, Nanchang, People’s Republic of China; 2Department of Pharmacy, The First Affiliated Hospital of Nanchang
Jing Y, Liu H, Peng H, Fu Q, Jiang X, Wei X, Kong Y, Rexiti K   +7 more
core  

Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw

Oral Diseases, EarlyView.
ABSTRACT Objective This study aimed to assess the occurrence of medication‐related osteonecrosis of the jaw (MRONJ) in mice following the sequential administration of romosozumab and zoledronate and to confirm their inhibitory effects on osteoclast differentiation in vitro.
Hae‐Seo Park, Shihyun Kim, Seo‐Yeong An, Reuben H. Kim, Jongho Choi, Moon‐Young Kim   +5 more
wiley   +1 more source

A Case of Recurrent Pulmonary Tumor Thrombotic Microangiopathy Associated With Gastric Adenocarcinoma Following Imatinib Discontinuation

Pulmonary Circulation
Pulmonary tumor thrombotic microangiopathy (PTTM) is a severe and fatal disease that rapidly causes pulmonary hypertension (PH). While imatinib shows potential for treating PH related to PTTM, it remains unclear if imatinib should continue or be ...
Atsumasa Kurozumi, Shun Minatsuki, Masaru Hatano, Takayuki Tsujimoto, Gota Fujisawa, Satoshi Ishii, Hiroki Yagi, Mai Shimbo, Masako Ikemura, Mitsuhiro Fujishiro, Norihiko Takeda   +10 more
doaj   +1 more source

Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term

, 2006
BACKGROUND/AIMS: Transactivated hepatic stellate cells (HSCs) represent the key source of extra cellular matrix (ECM) in fibrotic liver. Imatinib, a potent inhibitor of the PDGF receptor tyrosine kinase, reduces HSC proliferation and fibrogenesis when ...
Reichen, Juerg, Saegesser, Hans, Neef, Markus, Widmer, Nicolas, Ledermann, Monika, Decosterd, Laurent Arthur, Schneider, Vreni, Rochat, Bertrand   +7 more
core   +1 more source

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson, Kala A. Early, Maritza A. Morales, Klaudia A. Poplawski, Sunetra Das, Dawn L. Duval   +5 more
wiley   +1 more source

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.

, 2014
Pulmonary involvement represents a major cause of death of systemic sclerosis (SSc) patients. Recent data suggest that tyrosine kinase inhibitors, such as imatinib, may be a therapeutic option for SSc patients.
Malorni W, Moroncini G, Gabrielli A, Gabrielli B, LUNARDI, Claudio, Imatinib in Scleroderma Italian Study Group, Riboldi P, Gabrielli A., Pomponio G, Fraticelli P, Gerli R, Corvetta A, Bosello S, Del Papa N, Gerosa M, Faggioli P, Bombardieri S, Valentini G, Giacomelli R, Lunardi C, BOMBARDIERI, STEFANO, GERLI, Roberto   +21 more
core   +1 more source

Urokinase Plasminogen Activator Receptor‐Associated Protein (uPARAP) as a Potential Next Generation Molecular Target for Treatment of Gastrointestinal Stromal Tumors (GIST)

International Journal of Cancer, Volume 159, Issue 3, Page 797-808, 1 August 2026.
A key component of the collagen internalization and lysosomal degradation cellular machinery, uPARAP may contribute to cancer progression. Here, the authors explored the expression of uPARAP in gastrointestinal stromal tumors using well‐annotated clinical patient samples and specimens from cell line‐ and patient‐derived xenografts.
Chao‐Chi Wang, Flavia Paternostro, Agnieszka Wozniak, Lore De Cock, Luna De Sutter, Kimberly Verbeeck, Ulla Vanleeuw, Daniël Gorgels, Che‐Jui Lee, Raf Sciot, Patrick Schöffski   +10 more
wiley   +1 more source